These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7577084)
41. Gene marking after bone marrow transplantation. Brenner MK; Rill DR; Heslop HE; Rooney CM; Roberts WM; Li C; Nilson T; Krance RA Eur J Cancer; 1994; 30A(8):1171-6. PubMed ID: 7654451 [No Abstract] [Full Text] [Related]
42. Advances in the techniques and methodologies of cancer gene therapy. Sun W; Shi Q; Zhang H; Yang K; Ke Y; Wang Y; Qiao L Discov Med; 2019 Jan; 27(146):45-55. PubMed ID: 30721651 [TBL] [Abstract][Full Text] [Related]
44. From bench to community oncology clinic: the promise of immunotherapy. Chandra S Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP57-SP58. PubMed ID: 28298135 [No Abstract] [Full Text] [Related]
45. Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Vile RG; Diaz RM; Castleden S; Chong H Biochem Soc Trans; 1997 May; 25(2):717-22. PubMed ID: 9191190 [No Abstract] [Full Text] [Related]
46. [A balance of clinical trials in gene therapy]. Favrot MC; Coll JL; Puisieux I Bull Cancer; 1999 Jan; 86(1):115-21. PubMed ID: 10029714 [No Abstract] [Full Text] [Related]
47. Optimizing magnetic nanoparticle design for nanothermotherapy. Gazeau F; Lévy M; Wilhelm C Nanomedicine (Lond); 2008 Dec; 3(6):831-44. PubMed ID: 19025457 [TBL] [Abstract][Full Text] [Related]
48. The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK Stem Cells; 1995 Sep; 13(5):453-61. PubMed ID: 8528094 [TBL] [Abstract][Full Text] [Related]
49. Hematoprotection by transfer of drug-resistance genes. Flasshove M; Moritz T; Bardenheuer W; Seeber S Acta Haematol; 2003; 110(2-3):93-106. PubMed ID: 14583669 [TBL] [Abstract][Full Text] [Related]
50. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Heslop H; Rooney C; Brenner M; Krance R; Carrum G; Gahn B; Bollard C; Khan S; Gee A; Popat U; Gresik M; Przepiorka D; Kuehnle I; Grilley B Hum Gene Ther; 2000 Jul; 11(10):1465-75. PubMed ID: 10910143 [No Abstract] [Full Text] [Related]
52. Immunotherapeutic strategies for neoplasia. Talmadge JE Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659 [No Abstract] [Full Text] [Related]
53. Gene Therapeutic Approaches to Overcome ABCB1-Mediated Drug Resistance. Lage H Recent Results Cancer Res; 2016; 209():87-94. PubMed ID: 28101689 [TBL] [Abstract][Full Text] [Related]
59. From the editor. Bridging the gap between biostatistician and oncologist. Bates SE Clin Cancer Res; 2008 Oct; 14(19):5953. PubMed ID: 18829472 [No Abstract] [Full Text] [Related]